within Pharmacolibrary.Drugs.ATC.P;

model P01BD01
  extends Pharmacokinetic.Models.PK_1C_enteral(
    weight         = 70,
    F              = 0.87,
    Cl             = 4.0000000000000003e-07,
    adminDuration  = 600,
    adminMass      = 75 / 1000000,   // mg → kg
    adminCount     = 1,
    Vd             = 0.0023,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,
    ka             = 0.0009333333333333333,
    Tlag           = 600
  );

  annotation (Documentation(
    info       = "<html><body><table><tr><td>Drug:</td><td>P01BD01</td></tr><td>route:</td><td>oral</td></tr><tr><td>n-compartments</td><td>1</td></tr></table><p>Pyrimethamine is an antiparasitic compound primarily used in combination therapy for the treatment and prevention of malaria, particularly due to its activity against Plasmodium falciparum. It has also been used to treat toxoplasmosis, in combination with a sulfonamide. The drug acts by inhibiting dihydrofolate reductase, disrupting folic acid metabolism in parasites. Pyrimethamine remains in clinical use today.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic parameters reported in healthy adult volunteers following oral administration.</p><h4>References</h4><ol><li><p>Iida, T, et al., &amp; Gross, AS (2020). Evaluation of the Pharmacokinetics, Safety, and Tolerability of a Single Oral Dose of Pyrimethamine in Healthy Male Subjects of Japanese and European Ancestry. <i>Clinical pharmacology in drug development</i> 9(6) 768–773. DOI:<a href=\"https://doi.org/10.1002/cpdd.771\">10.1002/cpdd.771</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/31950646/\">https://pubmed.ncbi.nlm.nih.gov/31950646</a></p></li><li><p>Morris, CA, et al., &amp; Fleckenstein, L (2011). Review of the clinical pharmacokinetics of artesunate and its active metabolite dihydroartemisinin following intravenous, intramuscular, oral or rectal administration. <i>Malaria journal</i> 10 263–None. DOI:<a href=\"https://doi.org/10.1186/1475-2875-10-263\">10.1186/1475-2875-10-263</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/21914160/\">https://pubmed.ncbi.nlm.nih.gov/21914160</a></p></li><li><p>Zuidema, J, et al., &amp; Merkus, FW (1986). Clinical pharmacokinetics of dapsone. <i>Clinical pharmacokinetics</i> 11(4) 299–315. DOI:<a href=\"https://doi.org/10.2165/00003088-198611040-00003\">10.2165/00003088-198611040-00003</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/3530584/\">https://pubmed.ncbi.nlm.nih.gov/3530584</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>06/2025 initial model generated by LLM gpt-4.1 from general data</li></ul></body></html>"
  ));
end P01BD01;
